CV Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE

3 Months Ended

Mar. 31, 2023

The Company computes basic net income (loss) per share using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares plus potential common shares. The Company's stock options, including those with performance conditions, are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive.

The following common stock equivalents were not included in the calculation of net income (loss) per diluted share because their effect were anti-dilutive (in thousands):


	Three months ended March 31,
	2023	2022
Stock options	20,481	18,041
Performance stock options	11,000	11,000
Warrants	10,750	10,750
Convertible notes	—	7,623
Convertible preferred shares	—	10,000
Total	42,231	57,414